|Precision Therapeutics is a CLIA-certified clinical laboratory|
New Data Shows Unparalleled Overall Survival Improvement with ChemoFx®
A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer
Thomas Rutherford, James Orr Jr., Edward Grendys Jr., Robert Edwards, Thomas C. Krivak, Robert Holloway, Richard G. Moore, Larry Puls, Todd Tillmanns, Julian C. Schink, Stacey L. Brower, Chunqiao Tian, Thomas J. Herzog
This study demonstrates improvement in progression-free and overall survival for both platinum-sensitive and platinum-resistant recurrent ovarian cancer when patients are treated with agents identified as sensitive by ChemoFx.
- ChemoFx results were associated with a 14 month (65%) increase in mean overall survival and a 50% improvement in progression-free survival
- Both overall and progression-free survival differences persisted after controlling for other factors through multivariate analysis (HR=0.66, p=0.02)
- The effect was similar in both platinum-sensitive and platinum-resistant tumors
14 Month Increase (65% Improvement) in OS (A.) and 50% Improvement in PFS (B.) in Patients Receiving ChemoFx Sensitive (S) Regimens
Can ChemoFx® identify sensitive treatments for persistent or recurrent ovarian cancer patients?
- 52% of study participants could have benefitted from assay-informed chemotherapy choice if physicians weren’t blinded to results
- Only ~25% of patients were treated with sensitive drugs when physicians were blinded to assay results
- If ChemoFx results were provided to physicians, the number of patients who received a sensitive drug could have more than doubled
- No single treatment accounted for more than 30% of treatments assessed in this study
Rutherford T, Orr Jr. J, Grendys Jr. E, Edwards R, Krivak TC, Holloway R, Moore RG, Puls L, Tillmanns T, Schink JC, Brower SL, Tian C, Herzog TJ, “A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer.” Gynecologic Oncology (2013), doi: 10.1016/j.ygyno.2013.08.009